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Despite significant progress, China faces the challenge of re-emerging schistosomiasis
transmission in currently controlled areas due, in part, to the presence of a range
of animal reservoirs, notably water buffalo and cattle, which can harbor Schistosoma
japonicum infections. Environmental, ecological and social-demographic changes in
China, shown to affect the distribution of oncomelanid snails, can also impact future
schistosomiasis transmission. In light of their importance in the S. japonicum, lifecycle,
vaccination has been proposed as a means to reduce the excretion of egg from cattle
and buffalo, thereby interrupting transmission from these reservoir hosts to snails. A
DNA-based vaccine (SjCTPI) our team developed showed encouraging efficacy against
S. japonicum in Chinese water buffaloes. Here we report the results of a double-blind
cluster randomized trial aimed at determining the impact of a combination of the SjCTPI
bovine vaccine (given as a prime-boost regimen), human mass chemotherapy and snail
control on the transmission of S. japonicum in 12 selected administrative villages around
the Dongting Lake in Hunan province. The trial confirmed human praziquantel treatment
is an effective intervention at the population level. Further, mollusciciding had an indirect
∼50% efficacy in reducing human infection rates. Serology showed that the SjCTPI
vaccine produced an effective antibody response in vaccinated bovines, resulting in a
negative correlation with bovine egg counts observed at all post-vaccination time points.
Despite these encouraging outcomes, the effect of the vaccine in preventing human
infection was inconclusive. This was likely due to activities undertaken by the China
National Schistosomiasis Control Program, notably the treatment, sacrifice or removal of
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bovines from trial villages, over which we had no control; as a result, the trial design was
compromised, reducing power and contaminating outcome measures. This highlights
the difficulties in undertaking field trials of this nature and magnitude, particularly over
a long period, and emphasizes the importance of mathematical modeling in predicting
the potential impact of control intervention measures. A transmission blocking vaccine
targeting bovines for the prevention of S. japonicum with the required protective efficacy
would be invaluable in tandem with other preventive intervention measures if the goal of
eliminating schistosomiasis from China is to become a reality.
Keywords: schistosomiasis japonica, China, CRT, bovine vaccine, mathematical modeling
INTRODUCTION
Schistosomiasis, caused by Schistosoma japonicum,
threatened many millions of people in the People’s Republic
of China (P.R. China) prior to initiation of the national
schistosomiasis control program in the 1950s when nation-wide
surveys identified 12 provinces as endemic, mostly in the south,
with 12 million people infected (600,000 advanced cases), and
100 million people at risk of infection (1, 2). Based on the
habitat of the Oncomelania hupensis snail intermediate hosts,
the endemic areas for zoonotic schistosomiasis japonica in the
P.R. China are classified as one of three area types: the lakes
and marshlands, situated in Hunan, Jiangxi, Anhui, Jiangsu, and
Hubei (currently accounting for over 95% of the snail habitats
in the country); hilly and mountainous regions of the upper
reaches of the Yangtze River in Sichuan and Yunnan (4.91%);
and the plains region, with waterway networks (0.03%), mainly
located along the Yangtze River (2). The majority of S. japonicum
transmission, which occurs annually from April to October/early
November, is predominantly around the Dongting Lake (Hunan
Province) and Poyang Lake (Jiangxi Province), China’s two
largest lakes (2).
The national schistosomiasis control program for the
P.R. China achieved transmission control by the mid-1980s,
introduced mass chemotherapy and morbidity control by the
early 2000s, and has now transitioned to integrated control
approach (3). The Chinese government included schistosomiasis,
together with three other diseases (AIDS, TB, and Hepatitis
B), in the 11th and 12th 5 Year Plan (2005–2015) as one
of four main infectious diseases to target for elimination (4).
As a result, control efforts were intensified at this time with
the aim of reducing the overall infection prevalence to 1%
by 2015. The control/elimination program employed a multi-
sectoral, collaborative approach that embraced environmental
modification, snail control, health education, and chemotherapy.
Over the next 10 years, five provinces achieved the national
transmission interruption target (i.e., zero infections in humans,
animals and snails), with seven other provinces achieving the
national transmission control target (i.e., infection prevalence
of <1%). Areas endemic for schistosomiasis were reduced from
12 provinces (Jiangsu, Zhejiang, Anhui, Jiangxi, Fujian, Hunan,
Hubei, Guangdong, Sichuan, Yunnan, Shanghai, Guangxi) to
seven provinces (Hubei, Hunan, Anhui, Jiangxi, Jiangsu, Sichuan,
Yunnan) (5–8). Schistosomiasis cases declined substantially from
240,000 (30,000 advanced cases) by the end of 2012, and
to 77,190 in 2015; no acute cases have been reported since
2015 (9, 10).
Despite these great strides and considerable achievements,
China still faces the challenge of re-emerging transmission in
currently controlled areas due, in part, to the presence of
more than 40 animal reservoir species capable of harboring S.
japonicum infections (2, 3), with over 75% of schistosomiasis
transmission attributed to water buffalo and cattle. Recent
environmental, ecological, and social-demographic changes such
as the effects of global warming and the construction of the
Three Gorges Dam on the Yangtze, recently shown to affect the
distribution of oncomelanid snails, also have the potential to
impact on transmission (11, 12).
In addition to the employment of the customary interventions
(chemotherapy, mollusciciding, health education), the current
integrated control strategy focuses on interrupting bovine-
snail transmission by replacing bovines with mechanized
farming, prohibiting the pasturing of animals near lakes and
rivers, raising livestock in herds, and creating safe grazing
areas. Supplying safe water, building lavatories and latrines,
constructing marsh-gas pools, and providing fecal-matter
containers for fishermen’s boats are aimed at interrupting
human-snail transmission (13). However, some interventions
may not be effective for all areas. For example, replacing
bovines with tractors may not be practical for particular
terrains (14).
In light of their importance as major reservoirs for S.
japonicum, vaccination of bovines has been proposed as a
tool to assist in long-term prevention (2, 15, 16), supported
by mathematical modeling (17); the intervention would be
particularly applicable for areas where mechanical farming is
unsuitable. Vaccination can reduce egg excretion from cattle
and buffalo, thereby interrupting transmission from bovines to
snails. A schistosome plasmid DNA vaccine (SjCTPI-Hsp70) our
team developed showed very good efficacy against S. japonicum
in Chinese water buffaloes, when it was co-administered with
an IL-12 expressing plasmid as adjuvant (18). The present
paper reports the results of a double-blind cluster-randomized
controlled trial (CRT) using a multi-factorial randomized design
around the Dongting Lake area of Hunan province in P.R.
China over the period 2010–2014. The trial aimed to determine
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the impact of a combination of human mass chemotherapy,
snail control through mollusciciding and the SjCTPI bovine
vaccine, on the transmission of S. japonicum; the trial profile
(Supplementary Figure 1) and baseline results were reported
previously (19). The design of the trial (Table 1) is technically
known as a “split-plot” design. Developed by RA Fisher in 1925
(20), it was initially used for agricultural testing of fertilizers—
where one set of treatments is allocated randomly to predefined
“plots” of land (usually predefined subdivisions of a larger area,
e.g., gridded squares), then these plots are each subdivided to
sub-plots which are then used to test another set of treatments.
As far as we are aware this type of factorial design has not
been applied hitherto in field/clinical trials of populations before.
Furthermore, this study is the first to report on the outcomes of
a CRT to test a schistosomiasis transmission blocking vaccine in
the field.
MATERIALS AND METHODS
Trial Setting, and Baseline and
Follow-Up Surveys
The CRT was conducted in 12 administrative villages (Baitang,
Ganzhou, Nandi, Shuangzhou, Yuantan, Dongguo, Tuandong,
Changjiang, Tuqiao, Xihuyuchang, Chunfeng, and Beihu) in the
Dongting Lake area in Hunan province from 2010 to 2014,
and aimed to quantify the effects of integrated interventions
for eliminating S. japonicum (19). Hunan was selected as the
study site because it is an endemic province, with relatively
high infection rates, comparatively, in a setting of pre-
elimination, many counties in the province are located close
to the Lake, and a large stable rural population is at risk of
being infected or re-infected with S. japonicum. A baseline
survey was conducted in October to November 2010 and the
interventions were implemented in six intervention groups
from 2011 to 2013. In brief, the baseline survey included: (i)
Collection of a human stool sample, which was tested for S.
japonicum infection using the miracidial hatching test (MHT)
(two stools/three hatches per stool-30 g feces/hatching; read
blind) (19), after which the Kato Katz thick smear technique was
used on positive samples to determine the infection intensity
[Geometric Mean Eggs per Gram (GMEPG)] (19); (ii) A
TABLE 1 | Intervention matrix conceptually highlighting the factorial study design
used in village groups A–F. Reprinted from Gray et al. (19) with permission from
Elsevier.
Intervention Bovines given
active vaccine
Bovines given
placebo vaccine
Mollusciciding 2 villages (A) 2 villages (B)
Human treatment 2 villages (C) 2 villages (D)
Neither 2 villages (E) 2 villages (F)
control
“A” villages received mollusciciding + bovine Schistosoma japonicum triosephosphate
isomerase (SjCTPI) vaccine. “B” villages received mollusciciding + bovine placebo
vaccine. “C” villages received human treatment (praziquantel, PZQ) + bovine SjCTPI
vaccine. “D” villages received human treatment (PZQ) + bovine placebo vaccine. “E”
villages received bovine SjCTPI vaccine. “F” villages received bovine placebo vaccine.
questionnaire survey of village residents to collect information
on demographic variables, medical history and water contact
(19); (iii) Collection of bovine stool samples, which were tested
for S. japonicum infection using the MHT (one stool/three
hatches −50 g feces/hatching; read blind), followed by the
formalin-ethyl acetate sedimentation-digestion (FEA-SD) test
for positive samples to determine infection intensity (19); and
(iv) Oncomelanid snail surveys using the Chinese method of
random quadrat sampling applied to marshland areas for each
village (19).
Villages were then pair-matched for the CRT based on
historical prevalence and transmission ecology (19). One of
three intervention types (no specific intervention (control),
human mass praziquantel (PZQ) treatment, mollusciciding)
was randomly assigned to each pair to achieve two pairs per
intervention type. Within each pair, one village was randomly
assigned the active vaccine for vaccinating bovines and the other
village received a placebo vaccine. Bovines received the priming
SjCTPI DNA vaccine and protein boost, or placebo control, in
2011 with subsequent booster vaccinations or placebo controls
given in 2012 and 2013. All animals present on the marshland
at any particular time with active water contact received the
vaccine or placebo. Full details of the production and formulation
of the SjCTPI vaccines (plasmids encoding SjCTPI-HSP70
and UMVC3-mIL12 and recombinant SjCTPI) and placebo
control vaccine, the prime (DNA) and boost (recombinant
protein) vaccination regimen, and the procedures for injecting
bovines with the vaccine/placebo formulations have been
provided (19).
The investigators, including the research team, and study
participants were blind to the vaccine allocation. Following
the baseline survey, all residents (40 mg/kg) and bovines
(25 mg/kg) were treated with PZQ. Human mass treatment
with PZQ was carried out annually in the two randomly
selected village pairs. Mollusciciding (following the annual
snail surveys in March/May, 2011, 2012, 2013, and 2014
in two other randomly chosen village pairs) targeted snail
“hotspots” (areas close to human habitation with maximum or
daily access to both human and bovines in an environment
favored by snails), which were sprayed with niclosamide
(2 g/m2) annually.
Study Subjects, Data Collection,
and Management
Questionnaire survey data and results of the stool examinations
were collected during the baseline survey in October-November
2010 and at follow-ups in October-December from 2011 to 2013.
Baseline and follow-up data for each village were cleaned and
combined for the analyses in this paper. Based on specified
inclusion criteria (19), 6,177 participants (out of a total of 8,066
villagers in the 12 villages assessed for eligibility at baseline)
were selected to participate in the CRT (Figure 1). Inclusion
criteria for each subject included: (i) age 5–65 years; (ii) had
been a resident in the village for >12 months; (iii) would not
be migrating in the next 4 years; (iv) continuously resident in
the study area over the study period; (v) the resident provided
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FIGURE 1 | Trial recruitment, intervention allocation, and follow-up.
informed consent; and (vi) minors had the informed consent of
their parent/guardian.
Bovine Serology
The majority of bovines involved in the trial were water
buffaloes with only a small proportion being cattle. Sentinel
water buffaloes, selected randomly from all villages (total = 300
animals), were tagged and bled periodically. Blood samples were
taken prior to the commencement of vaccination (January, 2011);
after the priming vaccination and primary boost (May, 2011),
and then after post-boosts in May 2012 and April 2013. Serum
was harvested from each blood sample and stored at −80
◦
C
for serology which was performed at trial completion. Western
blotting (on a subset of sera) and indirect IgG ELISA were used
to determine levels of specific anti-SjCTPI antibodies and anti-
S. japonicum SEA (soluble egg antigens, SjCSEA) antibodies in
the bovine sera over the course of the trial (18, 19). In brief, 96-
well ELISA plates (Maxisorp Immuno; ThermoFisher, Scoresby,
Australia) were coated with 10µg/ml of recombinant SjCTPI
(18) or SjCSEA (21) diluted in carbonate coating buffer. The
plates were incubated at 37◦C for 1 h and then washed three times
with 0.05% Tween20 in PBS (PBST). The plates were blocked
with 2% casein in coating buffer for 1 h at 37◦C and then washed.
The freshly thawed bovine serum was diluted 1:100 in 1%milk in
PBST and duplicates were incubated for 1.5 h at 37◦C. The plates
were then washed four times including two times with 5min
of soaking. Diluted detection antibody (1:10,000 rabbit anti-
bovine IgG-HRP A5295, Sigma-Aldrich, Castle Hill, Australia)
was added to individual wells and the plates incubated for 1 h at
37◦C. The plates were washed four times with PBST. The reaction
was detected with TMB (3,3′5,5′-tetramethylbenzidine) substrate
(Scientific Research Special SRS, Changsha, China) and stopped
after 10min at room temperature with 5% (v/v) hydrochloric
acid. Positive controls were included on each SjCTPI and
SjCSEA ELISA plate. The positive control wells for the SjCTPI
plates were probed with a biotin-conjugated anti-His antibody
(mouse IgG2a, clone HIS-1 H1029, Sigma-Aldrich; targeting
the His-tag on the recombinant SjCTPI protein) followed by a
streptavidin-HRP (Pharmingen, San Diego, USA) detection step.
The positive control wells for the SjCSEA plates were probed
with a pool of highly reactive sera collected from bovines from
schistosomiasis japonica-endemic areas and detected with the
same method used for the other serum samples. The negative
control wells for both ELISA assays comprised a pool of sera
obtained from bovines collected from areas non-endemic for
schistosomiasis japonica. The plates were read with a plate reader
at OD450 and the duplicates averaged. To account for inter-
plate variation, the OD450 of the samples were normalized by
multiplying the ratio of the average of the positive controls across
all the plates to the plate-specific positive controls. Anti-SjCTPI
and anti-SjC SEA antibody OD450 levels for the control samples
(non-endemic, endemic positive and blank wells) are shown in
Supplementary Figures 2, 3.
Snail Surveys
Snail surveys used the Chinese method of random quadrat
sampling (0.11 m2 sized frames, 20m between frames) located
on the marshland areas appropriate for each village (19).
Statistical Methods
The study was designed to have 80% power to detect the
intervention effect, using intervention efficacy estimations for
vaccine (50%), human chemotherapy (85%), and mollusciciding
(75%). Calculations assumed an infection rate of 5–10%, and
a design effect of 1.5 to account for cluster effects, and 10%
loss-to-follow-up. A SAS program was written to carry out
the randomization to each intervention group. Analyses of
human infection were restricted to those who satisfied the initial
inclusion criteria and had baseline questionnaire and stool results
and at least one follow-up stool result.
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For intervention assessment the primary outcome was human
S. japonicum infection status at follow-ups in 2011, 2012, and
2013, with a positive infection defined as the presence of at least
one miracidium from the MHT (19). This was analyzed using
a logistic regression model to compare interventions (grouped
as control arm, human chemotherapy arm, mollusciciding arm,
and vaccine group) over time, using a year-intervention group
interaction. The models used Generalized Estimating Equations
(GEEs) to take account of clustering and repeated measures, with
an unstructured correlation structure for the latter. The model
included age group, sex, and baseline infection as covariates.
Contrasts were constructed to estimate the overall effect of each
intervention (averaged over other intervention groups) for each
follow-up year, and overall years. Subgroup effects were similarly
estimated for the effect of each intervention within each other
intervention group. Odds ratios and 95% confidence intervals
were estimated. Sensitivity analyses were conducted by restricting
analyses based on water contact exposure (at least monthly
exposure), occupation (farming and/or fishing) and season of
exposure (summer). Because of the large amount of missing data
on water contact, an imputed water contact was calculated, based
on the “last-observation-carried-forward” method.
All data management and analyses used SAS (r) Proprietary
Software 9.4 (TS1M2) [Copyright (c) 2002–2012 by SAS
Institute Inc., Cary, NC, USA, Licensed to UNIVERSITY
OF QUEENSLAND—EAS, Site 10005036]. Data were double
entered into a specially designed Microsoft Access-based
database we developed (19); electronic copies of all entered data
were saved oﬄine and backup paper duplicates were stored in a
secure location.
Mathematical Modeling
The modeling of schistosomiasis has important implications
when considering different control options. Models can predict
disease spread, the usefulness of different strategies for treatment
coverage, the effect of vaccines and the costs of control.
The elimination of schistosomiasis in China will rely on a
combination of different integrated control options, such as
mollusciciding, environmental modification, drug treatment
regimens, health education, improved sanitation, and bovine
vaccination could provide an important tool to assist in long
term prevention. That such a strategy could prove realistic gains
support from studies in China that show that the human-snail-
human cycle of transmission is less prominent than the animal-
snail-human cycle in sustaining schistosome infection (16). A
mathematical model was used to predict longer term effects post-
trial. This model is based on that developed by Williams et al.
(17), with extensions to include births and deaths of all hosts,
with constant net population, and an additional compartment
for all hosts to represent infection prior to infectiousness (22).
All models included a single human and bovine treatment with
efficacy 85% at the start of the intervention period (baseline).
The effects of no further intervention and three annual cycles
of human mass drug administration (HMA, coverage 80%)
and mollusciciding (efficacy 80%, coverage 90%) were modeled
separately. The combination of humanMDA andmollusciciding,
not one of the trial interventions, was also modeled. For each of
these scenarios, vaccine effects were modeled with 0, 25, 50, and
75% efficacy and 80% coverage.
RESULTS
Humans
A total of 8,066 residents from the 12 selected villages were
screened, with 6,177 satisfying the selection criteria (Figure 1).
Those for whom a stool sample was tested at each follow-up year
are shown in Figure 1. The number of follow-ups per person
varied from one to three, with some being available for a later
follow-up, but not an earlier one. The final analysis set, restricted
to those with at least one follow-up stool result, comprised 5,848
residents (Figure 1).
The overall prevalence of infection was 6.5% with infection
intensity in those infected being 15.5 GMEPG at baseline.
Baseline prevalence and infection intensity in 2010 and
cumulative prevalence and infection intensity in 2011–2013 are
shown by intervention arm (and vaccine group) in Tables 2, 3.
Human infection prevalence did not vary significantly among
intervention arms at baseline and prevalence decreased over time
in all groups, most noticeably in 2012 and 2013.
Infection intensity varied significantly among intervention
arms at baseline, with intensities being significantly lower in the
human chemotherapy arm compared to the control arm and
mollusciciding arm (P < 0.001 for both comparisons). Infection
intensity was significantly higher in the active vaccine group
compared with the placebo group within the control arm (P <
0.001). Infection intensity increased over time to 2013, although
this was variable and more apparent in the control and human
chemotherapy arms.
Bovines
All bovines (a total of 468 animals) present in the 12 villages were
examined at baseline, with a prevalence of infection of 11.8% and
an infection intensity of 5.5 GMEPG. Baseline prevalence and
infection intensity from 2010 to 2013 are shown by intervention
group in Tables 4, 5. There was no significant variation in bovine
infection prevalence or intensity at baseline.
The bovine vaccine coverage was high, ranging from 75.6
to 91.6%, overall 83.9% (Table 6). The vaccine and PZQ
treatment of bovines were well-tolerated with no direct adverse
effects recorded.
Modeling of Human Results
Table 7 shows the results of fitting the logistic regression of
human incident infection. Averaged over other intervention
arms and the post-baseline period, there was no significant
difference between active vaccine and placebo vaccine groups,
although the active vaccine group had higher rates of infection
in 2011 [OR = 1.44 95% CI (1.11, 1.86)]. Overall, human
chemotherapy and mollusciciding showed significant protective
effects in 2013 [OR = 0.55 (0.31, 0.96), OR = 0.55 (0.32, 0.96),
respectively]. The excess of infections within the active vaccine
group was specifically marked in the control arm [OR = 2.27
(1.52, 3.39)]. Over the post-baseline period, human treatment
and mollusciciding separately showed a halving of infection rates
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TABLE 2 | Human infection (%) by intervention group and year.
Group 2010 2011 2012 2013
Number
tested
Prevalence
(95% CI)
Number
tested
Prevalence
(95% CI)
Number
tested
Prevalence
(95% CI)
Number
tested
Prevalence
(95% CI)
*Control 2,009 6.7 (5.7, 7.8) 1,677 4.8 (3.5, 6.6) 1,696 3.5 (2.3, 5.1) 1,559 2.5 (1.7, 3.6)
Placebo vaccine 1,050 6.6 (5.2, 8.2) 812 3.3 (2.2, 4.9) 853 2.1 (1.3, 3.4) 738 1.8 (1.0, 3.0)
Active vaccine 959 6.8 (5.3, 8.6) 865 6.5 (4.9, 8.7) 843 5.2 (3.7, 7.1) 821 3.3 (2.3, 4.8)
Human treatment 1,729 6.5 (5.5, 7.8) 1,642 5.5 (4.0, 7.4) 1,530 2.5 (1.6, 3.8) 1,434 1.6 (1.0, 2.5)
Placebo vaccine 873 5.0 (3.8, 6.7) 838 4.8 (3.4, 6.6) 766 2.7 (1.7, 4.2) 719 1.9 (1.2, 3.3)
Active vaccine 856 8.1 (6.4,10.1)
10.1)
804 6.4 (4.7, 8.6) 764 2.3 (1.4, 3.8) 715 1.3 (0.7, 2.4)
Mollusciciding 2,110 6.2 (5.3, 7.3) 2,069 5.7 (4.3, 7.6) 1,850 2.8 (1.9, 4.2) 1,634 1.5 (1.0, 2.4)
Placebo vaccine 1,072 6.5 (5.2, 8.2) 1,051 6.5 (4.9, 8.4) 945 3.5 (2.4, 5.0) 900 1.9 (1.2, 3.0)
Active vaccine 1,038 5.9 (4.6, 7.5) 1,018 5.2 (3.8, 6.9) 905 2.3 (1.5, 3.6) 734 1.2 (0.6, 2.3)
Total 5,848 6.5 (5.9, 7.1) 5,388 5.3 (4.5, 6.4) 5,076 2.9 (2.3, 3.7) 4,637 1.8 (1.3, 2.4)
*Control, group received the placebo or SjCTPI vaccine only.
TABLE 3 | Human infection intensity in infected persons (Geometric Mean EPG; GMEPG) by intervention group and year.
Group 2010 2011 2012 2013
Number
positive
GMEPG
(95% CI)
Number
positive
GMEPG
(95% CI)
Number
positive
GMEPG
(95% CI)
Number
positive
GMEPG
(95% CI)
*Control 134 19.7 (13.7, 28.4) 84 32.1 (21.4, 48.1) 53 60.4 (34.2, 106.5) 37 35.0 (20.3, 60.4)
Placebo vaccine 69 15.9 (9.9, 25.6) 27 40.1 (24.9, 64.5) 19 84.0 (42.8, 164.8) 12 33.6 (16.9, 67.0)
Active vaccine 65 24.4 (15.2, 39.3) 57 26.4 (17.7, 39.4) 34 44.1 (23.1, 84.0) 25 36.4 (18.7, 70.6)
Human treatment 112 8.6 (5.9, 12.4) 91 11.3 (7.6, 16.7) 22 14.3 (7.9, 25.7) 12 17.5 (9.6, 31.8)
Placebo vaccine 44 7.8 (4.8, 12.9) 40 8.5 (5.6, 13.1) 9 8.9 (4.4, 18.1) 5 11.4 (5.3, 24.7)
Active vaccine 68 9.3 (5.8, 15.0) 51 14.8 (9.9, 22.3) 13 22.5 (11.3, 44.7) 7 26.4 (12.5, 55.6)
Mollusciciding 131 21.7 (15.0, 31.2) 121 20.9 (14.2, 30.7) 41 13.6 (7.7, 24.2) 22 15.5 (8.8, 27.5)
Placebo vaccine 70 23.5 (14.6, 37.7) 68 28.1 (19.2, 41.2) 28 12.3 (6.4, 23.6) 15 12.3 (6.2, 24.4)
Active vaccine 61 19.9 (12.3, 32.2) 53 15.4 (10.2, 23.2) 13 15.2 (7.6, 30.4) 7 19.9 (9.4, 42.3)
Total 377 15.5 (11.3, 21.2) 296 19.5 (14.0, 27.1) 116 22.9 (13.7, 38.5) 71 21.5 (14.4, 32.1)
*Control, group received the placebo or SjCTPI vaccine only. Discrepancies occur in the number positive and the number with non-zero GMEPG in Table 2: In 2010 1 person was MHT
positive and had a KK egg count of zero; in 2012, 1 person was MHT positive and did not have a KK egg count measured, and 41 persons had a KK egg count of zero; in 2013 these
figures were 1 and 17, respectively.
[OR = 0.48 (0.33, 0.70), OR = 0.50 (0.34, 0.76), respectively]
within the active vaccine group.
Table 8 shows the results of fitting the log-transformed
intensity (GMEPG) regression model. The active vaccine had
no overall effect on intensity. Within those receiving human
treatment, the active vaccine was associated with an increase in
intensity. Human treatment and mollusciciding were associated
with reductions in GMEPG of ∼60%: OR: 0.36 (0.29, 0.45) and
0.38 (0.31, 0.48), respectively.
Modeling of Bovine Results
An overall model could not be fitted to bovine infection
owing to zero prevalence in the placebo group within the
control arm. Separate models at 2011 and 2012 showed no
significant variation in infection rates among intervention
arms. A model for 2013 excluding the placebo vaccine group
within the control arm showed significant variation in the
remaining five intervention arm/groups, although there was no
consistent pattern with the active vaccine vs. placebo vaccine. The
active vaccine group within the human chemotherapy arm had
significantly lower infection rates at 2013, compared to average;
and both mollusciciding groups had significantly higher rates
of infection.
Bovine Serology
The active bovine vaccine group had a significantly higher level
of anti-SjCTPI IgG antibodies and a significantly lower level
of anti-SjC SEA IgG antibodies compared with the placebo
vaccinated group after receiving the priming vaccination and
primary boost (Table 9; Figure 2; Supplementary Figures 4, 5).
Western blot analysis of a subset of individual serum samples
obtained from the active priming vaccinated/boosted group at
this time point (May 2011) showed the reaction was specific as
sera from placebo-vaccinated bovines did not react with SjCTPI
(data not shown). The SjCTPI antibody response was maintained
after the second boost and increased after the third boost. There
was no significant difference in anti-SjC SEA response after either
booster (Table 9; Supplementary Figure 5).
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TABLE 4 | Bovine infection (%) by intervention group and year.
Group 2010 2011 2012 2013
Number
tested
Prevalence
(95% CI)
Number
tested
Prevalence
(95% CI)
Number
tested
Prevalence
(95% CI)
Number
tested
Prevalence
(95% CI)
*Control 145 10.3 (6.3, 16.5) 123 6.5 (3.1, 13.0) 94 6.4 (2.9, 13.5) 64 3.5 (0.3, 30.9)
Placebo vaccine 70 11.4 (5.8, 21.3) 67 6.0 (2.3, 14.9) 40 7.5 (2.4, 20.9) 26 0
Active vaccine 75 9.3 (4.5, 18.3) 56 7.1 (2.7, 17.6) 54 5.6 (1.8, 15.9) 38 8.3 (1.6, 34.07)
Human treatment 174 13.2 (8.9, 19.1) 166 10.3 (6.1, 17.0) 158 3.8 (1.7, 8.2) 160 3.6 (0.5, 21.1)
Placebo vaccine 62 14.5 (7.7, 25.6) 57 8.8 (3.7, 19.4) 58 3.4 (0.9, 12.8) 56 7.3 (1.6, 27.9)
Active vaccine 112 12.5 (7.5, 20.0) 109 11.0 (6.3, 18.4) 100 4.0 (1.5, 10.2) 104 1.4 (0.2, 9.6)
Mollusciciding 149 11.4 (7.2, 17.6) 118 12.2 (6.9, 20.6) 113 4.4 (1.8, 10.2) 83 21.8 (3.2, 70.5)
Placebo vaccine 92 7.6 (3.7, 15.1) 68 7.4 (3.1, 16.5) 63 3.2 (0.8, 11.9) 53 13.8 (3.1, 44.8)
Active vaccine 57 17.5 (9.7, 29.7) 50 18.0 (9.6, 31.2) 50 6.0 (1.9, 17.1) 30 56.9 (17.3, 89.3)
Total 468 11.8 (9.1, 15.0) 407 9.6 (7.1, 12.8) 365 4.7 (2.9, 7.4) 307 6.6 (1.9, 20.3)
*Control, group received the placebo or SjCTPI vaccine only.
TABLE 5 | Bovine infection intensity (GMEPG) in infected bovines by intervention group and year.
Group 2010 2011 2012 2013
Number
positive
GMEPG
(95% CI)
Number
positive
GMEPG
(95% CI)
Number
positive
GMEPG
(95% CI)
Number
positive
GMEPG
(95% CI)
*Control 15 5.1 (2.3, 11.1) 8 3.4 (1.0, 11.1) 6 13.2 (5.4, 32.4) 4 2.2 (0.9, 4.6)
Placebo vaccine 8 5.3 (1.8, 15.3) 4 2.8 (0.4, 17.9) 3 8.5 (2.6, 27.4) 0 –
Active vaccine 7 5.0 (1.6, 15.3) 4 3.9 (0.6, 24.9) 3 20.4 (6.3, 65.8) 4 2.1 (0.9, 4.6)
Human treatment 23 4.4 (2.7, 8.7) 17 3.4 (1.3, 9.8) 6 4.4 (1.8, 10.9) 6 1.8 (0.9, 3.4)
Placebo vaccine 9 7.7 (2.7, 21.6) 5 1.9 (0.1, 11.7) 2 4.6 (1.1, 19.3) 4 1.3 (0.6, 2.9)
Active vaccine 14 2.9 (1.2, 7.1) 12 5.2 (1.1, 23.9) 4 4.3 (1.6, 11.9) 2 3.1 (1.0, 9.7)
Mollusciciding 17 8.9 (4.2, 19.0) 14 1.1 (0.4, 3.1) 5 1.6 (0.6, 4.3) 28 4.9 (3.6, 6.6)
Placebo vaccine 7 8.7 (2.8, 26.8) 5 1.2 (0.2, 6.9) 2 4.1 (1.0, 17.1) 11 4.4 (2.8, 7.1)
Active vaccine 10 9.1 (3.3, 24.7) 9 1.0 (0.2, 5.0) 3 0.9 (0.3, 2.8) 17 5.3 (3.6, 7.8)
Total 55 5.8 (3.8, 8.7) 39 2.3 (1.2, 4.3) 17 4.5 (2.3, 9.1) 38 3.1 (1.8, 5.2)
*Control, group received the placebo or SjCTPI vaccine only.
TABLE 6 | Bovine vaccine coverage by intervention group.
Group Number Expected
number of doses
Number of
doses given
Coverage %
*Control 131 470 418 88.9
Placebo vaccine 68 233 201 86.3
Active vaccine 63 237 217 91.6
Human treatment 155 545 452 82.9
Placebo vaccine 64 225 183 81.3
Active vaccine 91 330 269 81.5
Mollusciciding 119 437 356 81.5
Placebo vaccine 63 236 204 86.4
Active vaccine 56 201 152 75.6
Total 405 1,462 1,226 83.9
*Control, group received the placebo or SjCTPI vaccine only.
The GM OD for anti-SjCTPI antibodies was significantly
higher in the active vaccine group than the placebo vaccine at all
post-vaccination time points (Table 9; Supplementary Figure 4).
The GMOD for anti-SjC SEA antibodies was significantly higher
in the placebo vaccine group at the first post-vaccination time
point in 2011 only (Table 9; Supplementary Figure 5).
The levels of anti-SjCTPI antibodies were negatively
correlated with bovine egg counts within the active vaccine
group at all post-vaccination time points, although there was a
positive correlation pre-vaccination (Table 10). Anti-SjC SEA
antibody levels were positively correlated with bovine egg counts
after the second booster injection (2012) within this group.
Within the placebo vaccine group, anti-SjCTPI antibody levels
were negatively correlated with egg counts after the second
booster injection (Table 10).
Snail Prevalence and Density of
Infected Snails
Snail density was highest in the mollusciciding villages at baseline
and decreased markedly over time. The density of infected snails
decreased in all intervention groups over time (Table 11).
Mathematical Modeling of
Intervention Arms
Results of the mathematical modeling are as shown in Figure 3.
The non-intervention model with zero vaccine efficacy shows
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TABLE 7 | Odds ratios (95% confidence intervals) and P-values for treatment effects on human incident infection, adjusted for baseline infection, sex, and age group;
derived from logistic regression using Generalized Estimating Equations (GEEs) for correlated data; participants satisfying initial inclusion criteria, with baseline infection
status measured and at least one follow-up stool measurement.
2011 2012 2013 All years
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
OVERALL EFFECTS
Vaccine 1.44 (1.11, 1.86) 0.0066 1.21 (0.85,1.73) 0.29 0.90 (0.57,1.43) 1.43) 0.65 1.16 (0.92,1.47)
1111.47)
0.22
Human treatment 1.19 (0.85, 1.67) 0.31 0.74 (0.47,1.16) 0.19 0.55 (0.31,0.96) 0.035 0.78 (0.59, 1.05) 0.10
Mollusciciding 1.28 (0.94, 1.74) 0.12 0.86 (0.56, 1.30) 0.47 0.55 (0.32,0.96) 0.96) 0.035 0.85 (0.64, 1.13) 0.25
VACCINE EFFECT
Control arm 2.30 (1.39, 3.80) 0.001 2.86 (1.56, 5.24) <0.001 1.78 (0.87,3.62) 3.62) 0.11 2.27 (1.52, 3.39) <0.001
Human treatment arm 1.33 (0.84, 2.10) 0.23 0.81 (0.41, 1.58) 0.53 0.59 (0.25,1.40) 1.40) 0.23 0.86 (0.56, 1.32) 0.48
Mollusciciding arm 0.98 (0.69, 1.38) 0.89 0.77 (0.44, 1.37) 0.38 0.69 (0.30, 1.59) 1.1.59) 0.39 0.80 (0.54, 1.20) 0.29
HUMAN TREATMENT
Placebo vaccine 1.57 (0.93, 2.65) 0.093 1.39 (0.70, 2.76) 0.35 0.95 (0.43, 2.13) 0.9 1.28 (0.82, 2.00) 0.29
Active vaccine 0.91 (0.59, 1.40) 0.66 0.39 (0.22, 0.71) 0.002 0.32 (0.15, 0.69) 0.004 0.48 (0.33, 0.70) <0.001
MOLLUSCICIDING
Placebo vaccine 1.96 (1.22, 3.14) 0.005 1.65 (0.88, 3.09) 0.12 0.89 (0.41, 1.92) 0.77 1.42 (0.95, 2.12) 0.084
Active vaccine 0.83 (0.56, 1.23) 0.36 0.45 (0.26, 0.77) 0.004 0.35 (0.16, 0.75) 0.008 0.50 (0.34, 0.76) <0.001
TABLE 8 | Relative increases in human GMEPG (95% confidence intervals) among positives and P-values for treatment effects, adjusted for baseline infection, sex, and
age group; derived from logistic regression using GEEs for correlated data; participants satisfying initial inclusion criteria, with baseline infection status measured and at
least one follow-up stool measurement.
2011 2012 2013 All years
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
OVERALL EFFECTS
Vaccine 0.86 (0.67, 1.09) 0.20 0.97 (0.73, 1.29) 0.86 1.16 (0.76, 1.78) 0.49 0.99 (0.81, 1.21) 0.92
Human treatment 0.35 (0.26, 0.48) <0.001 0.26 (0.19, 0.35) <0.001 0.51 (0.31, 0.82) 0.006 0.36 (0.29, 0.45) <0.001
Mollusciciding 0.60 (0.43, 0.83) 0.002 0.24 (0.17, 0.33) <0.001 0.39 (0.26, 0.60) <0.001 0.38 (0.31, 0.48) <0.001
VACCINE EFFECT
Control arm 0.61 (0.36, 1.05) 0.08 0.51 (0.38, 0.68) <0.001 1.14 (0.86, 1.51) 0.38 0.71 (0.56, 0.88) 0.002
Human treatment arm 1.83 (1.46, 2.29) <0.001 2.22 (1.26, 3.91) 0.006 1.59 (0.63, 4.04) 0.33 1.86 (1.24, 2.79) 0.003
Mollusciciding arm 0.56 (0.37, 0.85) 0.007 0.83 (0.46, 1.47) 0.51 0.87 (0.38, 1.98) 0.74 0.74 (0.50, 1.09) 0.13
HUMAN TREATMENT
Placebo vaccine 0.21 (0.13, 0.34) <0.001 0.12 (0.07, 0.22) <0.001 0.43 (0.19, 0.97) 0.042 0.22 (0.15, 0.33) <0.001
Active vaccine 0.61 (0.45, 0.84) 0.002 0.54 (0.40, 0.73) <0.001 0.60 (0.35, 1.02) 0.06 0.58 (0.46, 0.74) <0.001
MOLLUSCICIDING
Placebo vaccine 0.63 (0.37, 1.06) 0.08 0.19 (0.13, 0.27) <0.001 0.45 (0.31, 0.64) <0.001 0.37 (0.29, 0.48) <0.001
Active vaccine 0.57 (0.38, 0.87) 0.009 0.30 (0.18, 0.52) <0.001 0.34 (0.16, 0.75) 0.007 0.39 (0.27, 0.57) <0.001
a rebound effect after the initial treatment with steadily
increasing prevalence to about half the baseline level after
10 years. Further human treatment results in greater short-
term decreases with a similar rebound effect upon cessation.
Mollusciciding maintains the post-initial treatment level until
its cessation, with subsequent rebound effects and steadily
increasing prevalence of infection. The vaccine with 25–75%
efficacy has the effect of reducing the rebound after mass drug
treatment or mollusciciding and further reducing the longer
term prevalence at 10 years to around 1%. The combination of
mass drug treatment and mollusciciding halves the effect of the
single interventions to about 1% immediately post-trial. This is
then maintained and then somewhat further reduced over the
10 year period.
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TABLE 9 | Geometric Mean (GM) antibody response (OD450) in bovines given vaccine or placebo, for each blood sample.
Vaccine Pre-vaccination
(Jan 2011)
Post primary
vaccination
(May 2011)
Post boost
(May 2012)
Post boost
(April 2013)
N GM OD*
(95% CI)
N GM OD
(95% CI)
N GM OD
(95% CI)
N GM OD
(95% CI)
SjC SEA
Placebo vaccine 83 0.266 (0.240, 0.294) 60 0.383 (0.344, 0.425) 53 0.286 (0.261, 0.312) 39 0.296 (0.264, 0.332)
Active vaccine 82 0.274 (0.249, 0.301) 69 0.301 (0.278, 0.326) 64 0.296 (0.272, 0.323) 46 0.293 (0.271, 0.316)
P value 0.66 <0.001 0.56 0.86
SjCTPI
Placebo vaccine 83 0.174 (0.162, 0.187) 60 0.210 (0.191, 0.231) 53 0.181 (0.165, 0.200) 39 0.192 (0.169, 0.217)
Active vaccine 82 0.197 (0.182, 0.213) 69 0.294 (0.264, 0.327) 64 0.234 (0.213, 0.258) 46 0.298 (0.256, 0.348)
P value 0.34 <0.001 <0.001 <0.001
*GM OD, Geometric Mean Optical Density.
FIGURE 2 | Anti-SjCTPI antibody OD450 levels in bovine serum samples for all
collection time points. The anti-SjCTPI IgG antibody levels (OD450) were
measured in sera from individual bovines collected pre-vaccination (January
2011), post primary vaccination (May 2011), post boost (May 2012), and post
boost (April 2013). Anti-SjCTPI antibody levels are compared for bovines given
active vaccine or placebo for all the collection time points. The box and
whisker plot display the median (central horizonal line), first and third quartiles
(bottom and top of box, respectively; inter-quartile range), and values within
1.5 times the inter-quartile range of the first and third quartiles (vertical lines).
DISCUSSION
Elimination of schistosomiasis is now on the immediate horizon
for P.R. China but it is important to evaluate which intervention
combinations will be needed to achieve this goal. We present
the outcomes of a double-blind cluster CRT using a multi-
factorial design undertaken in Hunan Province in 2010–2014.
We evaluated the impact of a combination of human mass
chemotherapy, mollusciciding and bovine vaccination—using
the SjCTPI vaccine—on the transmission of S. japonicum. This
is the first reported schistosomiasis field trial of its type and
magnitude, and the first to report on the outcomes of a CRT,
equivalent to a phase III clinical trial, to test a schistosomiasis
transmission blocking vaccine in the field.
Results of the multi-factorial trial revealed that human
praziquantel chemotherapy is indeed an effective intervention
at the population level showing an efficacy of ∼50% on human
infection and reinfection. Of particular note was our finding
that mollusciciding had an indirect ∼50% efficacy on human
infection rates; as far as we are aware, this is the first time that
such an outcome has been demonstrated.
Serology showed that the SjCTPI vaccine was effective in
inducing an antibody response in the bovine cohort. This
response was maintained over the course of the trial, and a
negative correlation with bovine egg counts was observed at all
post-vaccination time points. This is in line with the experimental
results obtained with the SjCTPI vaccine (18, 23) and reinforces
its potential for inducing specific anti-SjCTPI antibodies in
bovine hosts within their natural setting.
Despite this encouraging outcome, the effect of the SjCTPI
vaccine in preventing human infection was inconclusive in that
we were unable to show a difference in human infection rates
between the active vaccine and placebo vaccine groups. This is
likely due to a number of factors over the 4-year trial duration,
including: (a). In one control arm/active vaccine village and one
mollusciciding arm/placebo vaccine village, infected humans and
bovines were PZQ drug-treated from 2010 to 2012; (b). In one
control arm/placebo vaccine village all bovines were slaughtered
in 2012 and 2013 to control an outbreak of brucellosis; and (c). In
one mollusciciding arm/active vaccine village, the bovines were
removed in 2013 (Figure 4). These activities were undertaken
by the China National Schistosomiasis Control Program over
which we had no jurisdiction. In particular, the loss of bovines
compromised the trial design, resulting in reduced power
and the contamination of outcome measures necessary for
comparing the effect of the active vaccine with the placebo
vaccine. This highlights the difficulties in undertaking field
trials of this nature and magnitude, particularly over a long
period.Mathematical modeling results (discussed below) are thus
important in predicting the potential impact of the intervention
measures employed.
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TABLE 10 | Spearman’s correlations (rs) between bovine antibody responses to vaccine or placebo and bovine egg counts over the trial course.
SjC SEA SjCTPI
Pre-
vaccination
(Jan 2011)
Post primary
vaccination
(May 2011)
Post booster
(May 2012)
Post booster
(April 2013)
Pre-
vaccination
(Jan 2011)
Post primary
vaccination
(May 2011)
Post booster
(May 2012)
Post booster
(April 2013)
All N 93 71 82 75 93 71 82 75
rs −0.112 0.018 0.311 0.214 −0.173 −0.117 −0.329 −0.193
P-value 0.29 0.88 0.004 0.065 0.098 0.33 0.003 0.097
Placebo
vaccine
N 44 29 37 35 44 29 37 35
rs −0.157 0.205 0.264 0.180 −0.089 0.355 −0.454 −0.177
P-value 0.31 0.29 0.12 0.30 0.57 0.059 0.005 0.31
Active
vaccine
N 49 42 45 40 49 42 45 40
rs −0.113 0.037 0.348 0.249 0.312 −0.408 −0.385 −0.324
P-value 0.44 0.82 0.019 0.12 0.029 0.007 0.009 0.041
TABLE 11 | Snail density (per m2) and density of infected snails (per 100 m2).
Group No sites
2010
Snail
density
2010
Density
infected
snails
2010
No sites
2011
Snail
density
2011
Density
infected
snails
2011
No sites
2012
Snail
density
2012
Density
infected
snails
2012
No sites
2013
Snail
density
2013
Density
infected
snails
2013
*Control 14 1.94 3.21 16 1.47 0.47 18 0.82 0 16 0.86 0
Placebo vaccine 5 1.63 5.97 6 1.56 0.14 8 0.68 0 6 0.90 0
Active vaccine 9 2.21 0.75 10 1.42 0.10 10 1.04 0 10 0.80 0
Human treatment 10 5.41 1.54 20 3.32 0.40 20 2.59 0.13 12 4.90 0
Placebo vaccine 3 0.15 0.92 12 0.05 0.09 12 0.05 0 4 0.10 0
Active vaccine 7 7.30 1.76 8 6.85 0.74 8 5.33 0.28 8 6.77 0
Mollusciciding 30 12.4 0.47 36 8.51 0.19 28 4.62 0 26 3.47 0
Placebo vaccine 11 16.85 1.03 12 11.27 0.39 8 8.19 0 8 4.98 0
Active vaccine 19 9.74 0.14 24 6.82 0.07 20 2.38 0 18 2.46 0
Total 54 9.16 1.22 72 6.05 0.25 66 2.98 0.03 54 2.84 0
*Control, group received the placebo or SjCTPI vaccine only.
Mathematical modeling has been used to compare and
evaluate the impact of various strategies implemented for the
control and elimination of schistosomiasis in China (17, 24–
28). Here we used an updated version of the Williams et
al model (17) to simulate the trial and the combination of
interventions employed (human mass chemotherapy, snail
control through mollusciciding, and bovine vaccination).
The modeling clearly demonstrates that one intervention
alone will not work to eliminate schistosomiasis and indicates
that an approach integrating multiple interventions would
be the most effective in bringing down transmission and
sustaining the impact of a control program. Depending
on the level of immunological protection, the vaccine
was shown to be effective in reducing the rebound in
human infection to varying degrees following human
treatment and snail control through mollusciciding. A
75% efficacious vaccine in combination with these two
other interventions was shown to result in S. japonicum
elimination (i.e., <1% prevalence).
The Chinese Government continues in its commitment
toward the control of schistosomiasis, developing the new
national elimination plan for the period 2016–2020 (10, 29).
MDA is now used biannually in the lake areas among boat people
and fisher communities living close to water-bodies infested with
infected oncomelanid snails. Other high-risk populations with
extensive water contact are subjected to questionnaire surveys
or serology prior to selective PZQ treatment. Extensive drug
treatment of bovines has not reduced schistosomiasis prevalence
to acceptable levels and in, some areas, the replacement
of these animals with motorized tractors has proved more
effective in reducing transmission. Any control program with
the goal of schistosomiasis elimination must be mindful of
long-term sustainability. Much of China’s success in its goal of
achieving the elimination of schistosomiasis can be attributed
to strong, long-term government commitment and support.
The Chinese have recognized that a comprehensive multi-
facetted approach is most effective, but that any introduced
interventions need to be adapted to local conditions and
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FIGURE 3 | Mathematical modeling of the SjCTPI vaccine and integrated control strategies.
the associated economic costs need careful consideration.
Further, it is clear from the experiences, not only in China
but also the Philippines, Cambodia, and the Lao People’s
Democratic Republic that preventive chemotherapy as the sole
intervention is not sufficient to interrupt transmission of Asian
schistosomiasis (30).
However, for the long-term sustainability and effectiveness
of elimination efforts, preventive measures will become
increasingly important. The management of feces of fishermen
in areas with persistent transmission and further reducing
the infection prevalence in livestock are challenges that need
addressing (30). A transmission blocking vaccine targeting
bovines for the prevention of S. japonicum with the required
protective efficacy would be invaluable along with other
preventive intervention measures such as health education
and environmental modification for snail control in China.
Schistosomiasis vaccine development has, however, proven
highly challenging and it is a stark reality that no vaccine with
a sufficient level of protective efficacy is currently available
for schistosomiasis. Nevertheless, it is likely that the inclusion
of effective anti-schistosome vaccines as components of an
integrated intervention package will be required if long term
and universal control efforts against this disease are to prove
successful. Consequently, funding for vaccine research and
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FIGURE 4 | Events compromising the trial. In one control arm/active vaccine village and one mollusciciding arm/placebo vaccine village, infected humans and bovines
were PZQ drug-treated from 2010 to 2012 (demarcated by red circles). In one control arm/placebo vaccine village all bovines were slaughtered in 2012 and 2013 to
control an outbreak of brucellosis (demarcated by purple circles).In one mollusciciding arm/active vaccine village, the bovines were removed in 2013 (demarcated by a
blue circle).
the development of more specific, sensitive, rapid and cost-
effective diagnostic, and snail survey tools for active surveillance
should be strongly advocated if the goal of eliminating
schistosomiasis from China, and elsewhere, is to become a
reality (31–33).
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